BCL6B is regarded as a potential tumor suppressor, and methylation of BCL6B is a marker of poor prognosis in several human cancers, including gastric cancer [24–26], hepatocellular carcinoma [27, 28], and colorectal cancer [29]. This evidence concerns the gene BCL6B and colorectal cancer.